Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Gardasil / Gardasil 9 (HPV recombinant vaccine) by Year
Gardasil / Gardasil 9 (HPV recombinant vaccine) — International sales ($M) ($M)
Merck Gardasil / Gardasil 9 (HPV recombinant vaccine): $2,592M in FY2025, down 57.9% from a year earlier.
Where the FY2025 figure comes from
“|| Gardasil/Gardasil 9 | 5,233 | 8,583 | -39 | 2,641 | 2,425 | 9 | 2,592 | 6,158 | -58”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Gardasil / Gardasil 9 (HPV recombinant vaccine) — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,592 | -57.9% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 6,158 | -9.5% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 6,803 | +40.8% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 4,832 | +27.4% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 3,792 | +73.6% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 2,184 | +14.6% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 1,905 | +48.9% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 1,279 | +72.1% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 743 | +89.1% | Form 10-K (filed 2020-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 393 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up gardasil / Gardasil 9 (HPV recombinant vaccine)
Cite this data
StockData. (2026). Merck Gardasil / Gardasil 9 (HPV recombinant vaccine) ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-gardasil-intl
See every metric in the Merck KPI table. Data updated Oct 26, 2026.